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Co-ligation of the B cell antigen receptor with complement receptor 2 on B-cells via
a C3d-opsonised antigen complex significantly lowers the threshold required for B cell
activation. Consequently, fusions of antigens with C3d polymers have shown great
potential in vaccine design. However, these linear arrays of C3d multimers do not mimic
the natural opsonisation of antigens with C3d. Here we investigate the potential of using
the unique complement activating characteristics of Staphylococcal immune-evasion
protein Sbi to develop a pro-vaccine approach that spontaneously coats antigens
with C3 degradation products in a natural way. We show that Sbi rapidly triggers
the alternative complement pathway through recruitment of complement regulators,
forming tripartite complexes that act as competitive antagonists of factor H, resulting
in enhanced complement consumption. These functional results are corroborated by
the structure of the complement activating Sbi-III-IV:C3d:FHR-1 complex. Finally, we
demonstrate that Sbi, fused with Mycobacterium tuberculosis antigen Ag85b, causes
efficient opsonisation with C3 fragments, thereby enhancing the immune response
significantly beyond that of Ag85b alone, providing proof of concept for our pro-vaccine
approach.
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INTRODUCTION
Opsonisation of an antigen with C3d(g), the final degradation product of complement component
C3, results in the co-ligation of the B cell antigen receptor and complement receptor 2 (CR2) on
B cells, thereby instigating a profound molecular adjuvant effect, i.e., this co-ligation of receptor
complexes lowers the threshold of antigen required for B cell activation by up to 10,000 fold (1–3).
Furthermore, as CR2 is also expressed highly on follicular dendritic cells (FDCs) (4) the presence
of C3d(g) on the antigen allows it to be trafficked onto and trapped at the surface of these cells (5).
This provides an essential depot of antigen to support the germinal center reaction and maintain
the ongoing immune response including the generation of high affinity antibodies and memory
B-cells (3, 4, 6). B cells can also have an important role as antigen presenting cells (APCs) (7, 8) and
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have been shown to contribute to T-helper cell priming (9, 10)
and therefore, antigen-C3d-CR2 interactions play a key role in
humoral immunity (5). Additionally, C3d activation of T helper
cells has also been described in a CR2 independent manner (11),
underlining the importance of C3d opsonisation in stimulating
the immune system to respond.
Not surprisingly, this functionality led to the idea that
recombinant versions of C3d would make an ideal natural
adjuvant and to the subsequent design of linear polymers of
human C3d (12). Indeed, these linear arrays of C3d multimers
(3-mer to 20-mer) when fused directly to an antigen can act
as potent activators of human B-cells. However, they do not
mimic the natural opsonisation of antigens by C3d at a molecular
level and do not always enhance immune responses (13). After
activation of C3, C3b attaches directly to the antigen surface via
the reactive thioester on the convex face of the protein’s thioester
domain (TED). In the presence of complement regulators [factor
I (FI) and its co-factors, such as factor H (FH) and CR1] this
is rapidly converted to iC3b and then to C3d, exposing the
concave CR2 binding site of the TED fragment away from the
antigen surface (14). It is likely that multiple iC3b/C3d molecules
attach to complex antigens/pathogen surfaces during the initial
activation phases of complement, creating high-avidity binding
sites for complement fragment receptors.
In the last two decades, structural biology has helped to unveil
many of the molecular aspects that are crucial for the activation
and regulation of the complement system. Most notable are
the crystal structures of the central complement component
activation states, native C3 (15), activated C3b, and inactive
C3c (16). The structure of C3b in complex with factors B and
D (17) subsequently revealed a detailed view of the alternative
pathway C3 convertase assembly and its activation, leading to the
amplified cleavage of C3 molecules that result in opsonisation,
and clearance of microbial pathogens, and host debris. The
covalent attachment of C3b to surfaces does not discriminate
between self or non-self surfaces and requires tight regulation
to protect host surfaces. Structures of C3b in complex with FH
domains 1–4 (18) and domains 19–20 (19, 20) provided insights
into protection of host cells (21) and demonstrated how factor
H-related proteins (FHRs) function as competitive antagonists of
FH, modulating complement activation and providing improved
discrimination of self and non-self surfaces (22). The subsequent
structure of the complex of C3b, FH1−4, and regulator factor I
(23) improved our understanding in the proteolytic cleavage of
C3b to the late-stage opsonins iC3b or C3dg and provided the
basis for the regulator-dependent differences in processing and
immune recognition of opsonized material.
Here we investigate the potential to harness the unique
complement-stimulatory characteristics of Staphylococcus
aureus immunomodulator Sbi to develop “pro-vaccines.” Sbi
components would trigger natural complement activation
in the host and coat antigen surfaces with complement
component C3 degradation products, thereby enhancing
the degree of immunogenicity of target antigens. Research
from our lab previously revealed that Sbi contains two
domains (III and IV), which bind to the central complement
component C3 and cause futile fluid phase consumption
of this component (24). Therefore, these two domains of
Sbi offer the potential to not only coat an antigen with the
natural adjuvant C3d, but also to generate anaphylatoxins
and the full range of C3 opsonins. Such an approach has
the clear potential to activate many immune cells unlike
recombinant C3d fragment-based adjuvants of the past, that,
due to the restricted expression pattern of CR2, were largely
focused to B cells. Furthermore, the direct activation of
complement close to the target antigen (with the associated
anaphylatoxin generation) may be critical for generating
appropriate inflammatory immune responses, both humoral
and cellular; needed to immunize against complex pathogenic
targets.
In this study we first investigate the molecular mode
of action of Sbi-III-IV and evaluate the importance of
the tripartite complex formation between Sbi, C3d, and
complement regulators factor H (FH) or factor H-related
proteins (FHRs) for complement activation. Based on
these findings, we then tested whether our pro-vaccine
strategy would be successful by using Mycobacterium
tuberculosis antigen 85b (Ag85b) as a model antigen in a
fusion construct containing Sbi domains III and IV. We
show that this Sbi-Ag85b conjugate is opsonized by C3
degradation products in serum, and when administered to
mice, leads to an enhanced immune response in vivo, but
only in mice that possess C3 and complement receptor 1
and 2, demonstrating proof of concept for this adjuvant
compound.
RESULTS
Sbi-III-IV Triggers C3 Consumption via
Activation of the Alternative Complement
Pathway, Forming a Covalent Adduct With
C3b
To investigate the molecular details of the C3 futile consumption
caused by Sbi, a protein construct consisting of domains III
and IV (Sbi-III-IV) was incubated with normal human serum
(NHS) and analyzed using western blotting. As seen previously
(24), we found that Sbi-III-IV-induced C3 consumption results
in the deposition of metastable C3b molecules onto serum
proteins, causing the formation of high molecular weight
C3b covalent adduct species with serum proteins (Figure 1A).
Immuno-blotting analyses using a polyclonal anti-Sbi antibody
(Figure 1B) reveals that a small fraction of Sbi-III-IV molecule
also forms a covalent adduct with a nascent C3b molecule
that is subsequently converted into a smaller Sbi-iC3b adduct
as a result of proteolytic processing by serum proteases. In
addition, we show that Sbi-III-IV-induced C3 consumption
coincides with the release of the C3a anaphylatoxin fragment
(Figure 1C), and the proteolytic activation of factor B (FB)
(Figure 1D), confirming the alternative complement pathway
as the driving force behind this process. Pre-incubation of
serum with Sbi-III-IV results in the loss of serum hemolytic
ability caused by the futile consumption of fluid C3 (Figure 1E).
Without pre-incubation, the Sbi-III-IV construct does not
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FIGURE 1 | Sbi-III-IV induces C3 futile consumption via the alternative complement pathway and thereby causes C3b adduct formation and C3a anaphylatoxin
production. (A) C3 activation and C3b deposition in NHS after incubation with 10µM Sbi-III-IV, visualized using anti-C3d western blot analysis. C3b adducts formed
with serum proteins are indicated. Positions of α-120 (C3) α’110 (C3b) and α’-68 (iC3b) are indicated. The 10min lag-time in C3 activation we observe in the presence
of excess Sbi-III-IV (10µM) correlates with the delay reported in the natural C3 “tick-over” process, required for supplying the critical enzymatic component for the
initial fluid phase Alternative Pathway (AP) C3 convertase. (B) Sbi-C3b adduct formation, visualized with anti-Sbi western blot. These adducts migrate at higher than
expected molecular weights (Sbi-α’110: ∼160 kDa and Sbi-α’68: ∼120 kDa, with expected molecular weights of 125 and 83 kDa, respectively) which is caused by
the high pI of the Sbi-III-IV construct (pI = 9.3). Sbi-III-IV has a molecular weight of 14.8 kDa, but migrates to ∼22 kDa in SDS-polyacrylamide gel due to the positively
charged electrophoresis buffer. (C) C3a anaphylatoxin production, followed using anti-C3a western blot analysis (showing only the low molecular weight region). (D)
FB cleavage, monitored by anti-FB western blot analysis. (E) Concentration dependent Sbi-III-IV induced C3 consumption, studied by a rabbit erythrocytes haemolytic
assay. Rabbit erythrocytes were exposed to normal human serum pre-incubated with Sbi-III-IV (incubated, closed circles) and normal human serum with Sbi-III-IV
added at the start of the experiment (not incubated, open circles). (F) Schematic representation of the relative positions of point mutations that display the most
profound functional defects, K173A and R231A. (G) C3 consumption profiles of Sbi-III-IV mutants K173A and R231A. For (B–E) and (G), one representative blot of
three independent experiments was shown. For (E), four independent measurements of two experiments were shown. The mean and SD for each measurement were
calculated for all datasets. Curves were fitted using non-linear variable slope (four parameters) function in GraphPad Prism.
protect rabbit erythrocytes from lysis in NHS under AP
conditions.
Sbi Domain III Residue K173 Is Essential
for Complement Consumption
In order to gain understanding of the individual roles of Sbi
domains III and IV in AP activation, a systematic site-directed
mutagenesis approach was used, mainly focusing on charged
and polar amino acids (for details see Table S1 and Figure S1).
Functional screening of these mutants identified K173, located
within Sbi domain III (Figure 1F), as an essential contributor
to triggering C3 consumption. Sbi mutant K173A shows no
complement activation after 30min incubation with human
serum, demonstrating a comparable complement activation
defect to the previously identified C3d binding mutant R231A
(24, 25) (Figures 1F,G), located in Sbi domain IV. Assessment
of the C3d binding affinity, using switchSENSE (Table 1 and
Figure S2A), shows that contrary to R231A the C3d binding
capacity of K173A is unaffected, indicating it is essential for
the role for domain III in the futile consumption of C3.
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TABLE 1 | Sbi-III-IV:C3d interaction affinity determined by switchSENSE.
Kd (nM) kON (M
−1S−1) kOFF (S
−1)
WT:C3d 5.0 ± 0.8 5.9 ± 1.0×105 3.0 ± 0.1×10−3
K173A:C3d 5.8 ± 1.2 5.3 ± 0.9×105 3.0 ± 0.4×10−3
R231:C3d No binding
TABLE 2 | Sbi-III-IV:C3d complex hydrodynamic diameter determined by
switchSENSE.
DH (nm) of Sbi-III-IV DH (nm) of Sbi:C3d complex
WT 4.3 ± 0.1 6.6 ± 0.2
K173A 3.8 ± 0.3 5.0 ± 0.3
R231A 4.7 ± 0.3 No binding
Interestingly, our switchSENSE analyses of the C3d binding
characteristics also shows a reduced hydrodynamic diameter for
K173A compared to WT and the C3d impaired binding mutant
R231A, indication that this mutation in domain III results in
a more compact Sbi:C3d complex (Table 2 and Figure S2B). A
more detailed structural analysis of these conformational changes
follows below.
Sbi-III-IV Enhances Binding of FH or FHRs
to C3 Breakdown Products
In a previous study, we reported that Sbi-III-IV binds C3
isoforms in combination with the C-terminal part of FH
(FH19−20), forming tripartite complexes (26). Many FHRs
share SCR modules with high FH19−20 sequence identity (22)
particularly FHR-1 which has been demonstrated to have
significant complement dysregulation potential (21). Thus, we
investigated the potential role for Sbi-III-IV in mediating the
formation of tripartite complexes with C3 fragments and FHR-1,
FHR-2, or FHR-5.
On a C3b opsonised surface plasmon resonance (SPR) sensor
chip, the presence of wild-type Sbi-III-IV clearly enhanced
the binding of FH, FHR-1, FHR-2, FHR-5 as well as FH19−20
(at fixed concentrations of 100, 12.5, 20, 25, and 20 nM,
respectively) to the surface in a concentration dependent manner
(Figure 2A). However, in the case of the K173Amutant, tripartite
complex formation with FH or FHR-1, 2, 5, or FH19−20 is
significantly impaired, showing decreased binding and more
rapid dissociation compared to WT Sbi-III-IV (Figures 2B,C).
We also co-injected Sbi-III-IV with FH or FHR-1, flowing
opsonized iC3b or amine-coupled C3d(g) across the surface. On
these surfaces, the fold-changes in FH (or FHR-1) binding levels
were also enhanced even at reduced Sbi-III-IV concentration
(Figures S3A–D).
Sbi-III-IV Acts as a Competitive Antagonist
of FH via the Recruitment of FHRs
Our SPR data, described above, show that Sbi-III-IV enables
FH or FHR-1, 2 and 5 binding to the C3 activation fragment
C3b and late-stage proteolytic fragments iC3b and C3d(g). To
further our understanding of the mechanism of FH or FHR
recruitment and the contribution of these tripartite complexes
to AP complement activation, we used a rabbit erythrocyte
haemolytic assay. In the presence of Sbi-III-IV and endogenous
FH (and FHRs), in NHS, addition of recombinant FHR-1
or FHR-2 resulted in significantly enhanced C3 consumption
(Figure 3A), as evidenced by the reduction in erythrocyte lysis
in a concentration dependent manner. In the absence of Sbi-
III-IV only baseline C3 consumption was observed. Although
FHR-5 alone can reduce erythrocyte lysis in a concentration
dependent manner, as described previously (27), in the presence
of Sbi-III-IV C3 consumption by FHR-5 is clearly enhanced
(Figure 3B). As predicted, the results in Figure 3C indicate that
the observed reduction in erythrocyte lysis caused by C3 fluid
phase consumption, in the case of FHR1 and likely the remaining
FHRs, is mediated by the C-terminal SCR domains of the protein
rather than the N-terminal domains.
Whilst our SPR and rabbit erythrocyte assay clearly indicate
that in vitro Sbi-III-IV can recruit FHRs in tripartite complexes
with C3b and thereby enhance fluid phase complement
consumption, it has to be taken into account that the
physiological molar concentrations of FHR-1, 2, and 5 are 13–
164 fold less than that of FH (21, 28). To further investigate the
potential competitive binding between FH and the FHRs in Sbi-
III-IV mediated tripartite complexes, we used an ELISA-based
assay where we applied FH (25 nM) and Sbi-III-IV [1µM, in the
presence of a concentration range of FHRs (9.3–150 nM)] onto
a C3b coated plate. Subsequently, we assessed the percentage of
FH bound using monoclonal antibody OX-24. Figure 3D shows
that FHR-1 can compete with FH to bind C3b, decreasing the
percentage of residual FH bound to C3b from∼70% at the lowest
FHR-1 concentration to ∼30% at the highest concentration.
In the presence of Sbi-III-IV WT this effect is dramatically
increased with only ∼25% residual FH bound at the lowest
FHR-1 concentration, reducing to ∼0% at the highest FHR-
1 concentration (Figure 3E). These results clearly indicate that
Sbi-III-IV can preferentially recruit FHR-1 to form a tripartite
complex with C3b. Similarly, enhancement of recruitment was
observed with FHR-5 and fragment FH19−20 but only weakly
with FHR-2. Although unable to activate complement, Sbi-III-IV
mutant K173A is still able to compete for the binding of FHR-1
in the presence of FH, but its ability to enhance binding of FHR-2
and FHR-5 to C3b is clearly affected (Figure 3F).
To assess the potential AP de-regulatory roles of the Sbi-
III-IV mediated tripartite complexes we subjected them to a
novel C3 convertase decay acceleration activity (DAA) assay
and a fluid phase C3b co-factor activity (CFA) assay (29,
30). We demonstrated that in absence of Sbi, FHR-1 failed
to antagonize FH efficiently and show a difference in the
level of C3 convertase formation (Figure 3G). Co-injection
of FHR-1 and −5 shows reduced C3 convertase formation,
which is in accordance with the results from a previous study
(31). However, the presence of Sbi (2µM) potentiates the FH
antagonizing effect of FHR-1, and to a lesser extent that of
FHR-5, at a physiologically relevant concentration ratio (FH
2,000 nM: FHR-1 200 nM: FHR-5 20 nM), resulting in increased
C3 convertase formation on a C3b surface (Figure 3H). The
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FIGURE 2 | Surface plasmon resonance analyses of tripartite complexes. A triply diluted concentration series (4,050 to 1.8 nM) of (A) WT or (B) K173A Sbi-III-IV were
co-injected with plasma purified FH, recombinant FHR-1, FHR-2, FHR-5, or FH19−20. The red response curves were indicative of binding experiment in the absence
of Sbi. The co-injection experiments of a fixed analyte concentration in combination with increasing Sbi concentration were depicted by increasingly dark lines. (C)
Relative changes of Sbi-III-IV mediated FH (or FHR) binding to C3b. By subtracting the co-injection sensorgram (i.e., Sbi+FH) with the corresponding Sbi binding
dataset (Figure S3), the changes in FH (or FHRs) binding was deduced (Figure S3). Changes in FH (or FHRs) binding were expressed as the relative change, derived
from dividing the Sbi mediated binding by the FH (or FHR) only control, using the response-difference values at the equilibrated binding point (173.5 s). Each
sensorgram is representative of two experiments. Relative change curves were fitted using non-linear variable slope (four parameters) function in GraphPad Prism.
baseline C3b breakdown rate was acquired in the presence of FH
(0.160µM) and FI (0.017µM), and subsequent measurements
were performed in the presence of FHR alone (0.32µM) and
in combination with Sbi-III-IV (1µM). As shown in Figure 3I
and Figure S3F, the presence of FHR-1, 2 or 5 increases the C3b
fluid phase half-life to different degrees, with FHR-5 showing
the largest increase in half-life. Most interestingly, the C3b
half-life could be further extended by the addition of Sbi-III-
IV.
The Sbi-III-IV:C3d:FHR-1 Tripartite
Complex Forms a Dimer in Solution
To investigate the structural characteristics of the Sbi-III-
IV:C3d:FHR1 tripartite complex, we used small angle X-
ray scattering (SAXS). The scattering profile collected at an
equimolar mixing ratio is shown in Figure 4 in log plot (a) as well
as Kratky plot (b). The featureless descend in the log plot and the
plateau in the latter is characteristic for scattering of particles that
are, at least partially, disordered.
The SAXS data and the overall parameters obtained (Table S2)
suggest that the complex is largely dimeric but rather flexible
in solution. Quantitative flexibility analysis was performed
using the ensemble optimisation method EOM (32), which
fits the experimental data using scattering computed from
conformational ensembles. Models with randomized linkers
were generated based on the known structures of FHR-11−2
[3zd2, (21)]; FH18−20 [3sw0, (33)], containing the equivalent
of FHR-13; FH19−20:C3d complex [2xqw, (20)], corresponding
with FHR-14−5; and the Sbi-IV:C3d complex [2wy8, (34)]. To
account for the dimerisation, P2 symmetry was applied, using
the FHR-11−2 dimer interface as seen in the crystal structure
(3zd2). The distributions of the overall parameters in the
selected structures compared with those of the original pool
(Figure 4C) suggests that the complex is rather flexible with a
slight preference for extended structures in solution. The subset
of most typical models (and the volume percentage of their
contribution) shown in Figure 4C indicate that in addition to
the expected contact sites with C3d, Sbi-III domain appears to
also interact with FHR-1, corroborating the functional results
described above. Figure 4D shows a schematic representation
of the dimeric Sbi-III-IV:C3d:FHR-1 complex observed in
solution.
K173A Restricts the Conformational
Freedom of Sbi Domain III
To examine the possible structural effects of the K173A
substitution in Sbi domain III, SAXS data was collected on
the Sbi-III-IV(K173A):C3d complex, and compared to the
wild-type Sbi-III-IV:C3d complex published previously (34).
The experimental scattering pattern collected at 240µM (∼12
mg/ml) is presented in Figure 4E and the structural parameters
derived from this data are given in Table S2. The estimated
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FIGURE 3 | Functional characterization of tripartite complexes in complement AP regulation. NHS was incubated with Sbi-III-IV, in combination with specified
reagents or just buffer, the consumption of AP activity was indicated by the protection of rabbit red blood cell from lysis. (A) Pre-incubation of recombinant FHR-1
or−2 with the presence or absence of Sbi-III-IV. (B) Pre-incubation of recombinant FHR-5 in the presence or absence of Sbi-III-IV. (C) Pre-incubation of recombinant
FH19−20 or FHR-11−2 in the presence or absence of Sbi-III-IV. Using an ELISA assay, the ability of FHR-1,−2,−5, FH19−20, or FHR-11−2 to modulate FH binding to
a C3b coated surface was studied in the absence (D) or presence of WT Sbi-III-IV (E), or K173A Sbi-III-IV (F). C3 convertase formation in the absence (G) or presence
of Sbi-III-IV (H) was assessed by flowing factor B (500 nM) and factor D (100 nM) in the presence of FH (2,000 nM) or FH +FHR-1 (2,000 and 200 nM) or
FH+FHR-1&-5 (2,000, 200 and 20 nM) across a surface amine coupled with 500 RU C3b. To form Sbi bound C3 convertase, experiments were conducted in addition
of 2,000 nM of Sbi-III-IV. Detailed experimental and data processing procedures are provided in Materials and Methods and Figure S3E. (I) Percentage of intact C3b
derived from continuous recording of ANS fluorescence changes between 465 and 475 nm spectrum. Baseline C3b breakdown curve (−) was recorded in the
presence of FH and FI, interference caused by the addition of FHR-5 (+) or FHR-5 in combination of Sbi (++) was also examined. The data for FHR-1 and FHR-2 are
presented in Figure 3F. Normalized data was depicted in solid lines, simulated breakdown curves were shown as dotted-lines. Each curve represents the mean value
of three independent experiments. For (A–F), the mean and standard deviation for each measurement was calculated; For (G–H), each sensorgram is representative
of two experiments. For (I), simulated breakdown curves were fitted using one phase exponential decay function in GraphPad Prism.
molecular mass (MM) of the solute agrees within the errors with
the values predicted for a 1:1 complex (∼15 + 35 kDa). At
lower concentration a decrease in the MM estimates is observed
which suggests that the complex slowly begins to dissociate. The
previously described wild-type Sbi-III-IV:C3d data on the other
hand, suggests that at higher concentrations, higher oligomeric
species are present, thus, for the comparison here, data collected
at 0.6 mg/ml is shown. The faster descend of the wild-type data,
which translates to a larger Rg, suggests that rearrangements of
the flexible N-terminus lead to a more elongated particle (Rg
wild-type = 32.8 Å) as compared to K173A mutant (Rg K173A
= 30.6 Å). This is in strong agreement with the switchSENSE
analysis of the C3d binding characteristics, which show a
reduced hydrodynamic diameter for K173A compared to WT
(Table 2).
The ab initio low resolution models of the complex
reconstructed from the highest concentration data using
DAMMIF (35) showed a large cone shaped molecule with
a volume of 124 nm3 (Figure 4F). The resolution of the
reconstruction is estimated to be 29 ± 2 Å (36). The large
base of the cone can accommodate the crystal structure of
Sbi-IV:C3d complex (2wy8) (34). The extra space at the tip of
the cone would be sufficient to harbor the 60 N-terminal residues
comprising the Sbi-III domain. A more detailed modeling
was conducted with the program Coral (37), utilizing the
available high-resolution model of Sbi-IV:C3d and allowing for
60 additional beads to be added that mimic the missing Sbi-
III domain. Twenty independent Coral runs were performed
which all yielded models with a more or less structured N-
terminal region, suggesting that Sbi-III-IV(K173A) in complex
with C3d is conformationally restricted compared to wild-
type Sbi-III-IV. This is further supported by the narrow
distributions obtained with EOM (Figure S4B). Surprisingly,
whilst repeating these analyses using a proposed alternative
binding mode of the Sbi-IV:C3d complex (represented by
2wy7), where Sbi-IV is seen bound at the convex face of
C3d, the χ² value is greatly improved (Figure S4C). With this
modeling approach a similar restricted conformation is observed
for the N-terminus of Sbi-III-IV(K173A). Further studies are
currently being conducted to further investigate the potential
physiological relevance of this alternative Sbi-IV:C3d binding
mode.
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FIGURE 4 | Structural analysis of the Sbi-III-IV:C3d:FHR-1 tripartite complex. SAXS solution structure analysis and EOM modeling of the Sbi-III-IV:C3d:FHR-1 tripartite
complex: (A) Left panel, fit of the selected ensemble of conformers to the experimental scattering. Radius of gyration (Rg, middle panel), particle maximum dimension
(Dmax, right panel), and distribution histograms of the selected conformers vs. the pool. (B) Kratky plot of the tripartite complex. (C) Examples of rigid body models of
the selected conformers corresponding to the histogram peaks. The volume fraction of each species is indicated. The relative positions of C3d, Sbi-III-IV, and FHR-1
in the dimeric tripartite complex are indicated, with C3d in red, Sbi-IV in dark blue, Sbi-III in turquoise and FHR-1 in orange. (D) Schematic representation of the
dimeric Sbi-III-IV:C3d:FHR-1 tripartite complex. (E) Comparison of the solutions structure of wild-type Sbi-III-IV:C3d and mutated version Sbi-III-IV(K173A):C3d of the
dual complex. Radius of gyration (Rg), particle maximum dimension (Dmax), and distribution histograms of the selected conformers vs. the pool are shown in
Figure S4A. (F) Ab initio shape reconstruction shown as gray spheres in comparison to the partial crystal structure Sbi-IV:C3d (2wy8). (G) Examples of rigid body
models. Complete set of models as well as flexibility assessment is presented in Figure S5. C3d in shown red, Sbi-IV in dark blue, and Sbi-III in turquoise.
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A Fusion Construct of Sbi-III-IV With
M. tuberculosis Ag85b Activates the AP
To test the potential of Sbi-III-IV to induce C3d opsonisation in
a vaccine setting, a recombinant construct was designed whereby
Sbi-III-IV is fused to Mycobacterium protein Ag85b (Figure 5A,
and detailed in Figure S5A). Based on the SAXS structure
of the Sbi-III-IV:C3d:FHR-1 tripartite complex, revealing the
importance of a flexible and extended conformation of Sbi
domain III, we decided to attach Ag85b at the C-terminus of Sbi
domain IV and included a long flexible linker between Sbi-IV
and Ag85b to ensure accessibility and flexibility of the functional
domains. Expressed and purified fusion protein was subsequently
structurally and functionally characterized.
Circular dichroism analysis of the Sbi-III-IV-Ag85b fusion
indicates that the protein construct is folded and that the
secondary structural elements of both parent proteins have
been preserved (Figure S5B). SAXS data obtained for the fusion
protein demonstrate that both the Ag85b domain as well as
Sbi-IV domain are accessible (Figure 5B and Figure S5C).
Functional activity of the Sbi-III-IV-Ag85b fusion construct
was assessed using an AP complement activity assays (WIESLAB,
Euro Diagnostica), showing strong C3 depletion activity
(Figure S5D), whilst Ag85b on its own showed no complement
activating properties. These results confirm that the complement
activating properties of Sbi III-IV are not impaired as part of
the fusion construct. The western blot analyses presented in
Figure 5C and Figure S5E confirm these results, showing both
C3 activation and opsonisation by the Sbi-III-IV-Ag85b fusion
construct when incubated with NHS. Interestingly, C3 activation,
and consumption occur more rapidly with the fusion construct
when compared to Sbi-III-IV (Figures 1A,B) under the same
conditions. Whilst Sbi-III-IV shows opsonisation with a single
molecule of C3b (Figure 1B), the Sbi-III-IV-Ag85b fusion is
opsonized by 2 molecules of C3b that over time degrade to iC3b
and C3d (Figure 5C and Figure S5E). Interestingly, opsonisation
of Ag85b with C3 fragments also occurs when co-incubated with
Sbi-III-IV in NHS.
Sbi-III-IV Acts as an Adjuvant in Mice When
Immunized With Ag85b
Based on the ability of Sbi-III-IV to activate complement
[Figures 1B,C (human serum) and Figure 6A (mouse serum)]
and opsonise Ag85b with complement C3 break down fragments
(Figure 5C), we expected that this new fusion protein when
injected into mice would elicit a greater immune response to
the Sbi-III-IV-Ag85b fusion protein than Ag85b administered
alone (in PBS). Indeed, wild-type C57bl/6 mice immunized I.P.
(or I.V., data not shown) with Sbi-III-IV-Ag85b generated a >4
fold increase in immune response initially and following the
boost when compared to Ag85b alone (Figure 6B). Furthermore,
when mice were immunized with a mixture of Sbi-III-IV and
Ag85b (not fused together), this also resulted in a significantly
improved immune response, corroborating the role of C3
fragment opsonisation of the antigen in this process (see
Figure S5E). Subsequent, studies using C3−/− and Cr2−/− mice
clearly demonstrated that C3 and C3 breakdown fragment
receptors (CR1 and CR2) were essential for this “adjuvant”
function, respectively (Figure 6C). Overall, these data clearly
suggest that complement AP dysregulation function of the
Sbi-III-IV domain can be harnessed to improve immune
responses through the coating of antigens with C3 breakdown
fragments.
DISCUSSION
Previous work from our group (24) revealed that Staphylococcus
aureus immunomodulator Sbi binds complement component
C3 within the thioester domain of C3 or the C3dg portion
of the molecule and resulted in futile consumption of C3 via
uncontrolled activation of the AP. In this study, we endeavored
to both understand the mechanism of action of Sbi-III-IV and
harness it; in order to develop pro-vaccines which would trigger
natural complement activation and thereby coat antigen surfaces
with complement component C3 degradation products, generate
anaphylatoxins at the site of immunization and strongly enhance
the immunogenicity of antigens (Figure 6D).
The seminal studies by Pepys (38), using C3
activating/depleting agents including cobra venom factor
and Zymosan, clearly demonstrated intact C3 function was
important for the T-dependent response (38). A molecular
mechanism explaining this effect was established by Fearon
and Carter (39) supported by studies in both C3 (40) and Cr2
(complement receptor type I and II) knock-out mice (41).
Dempsey et al. exploited these findings and established that
multiple copies of C3d, in a linear trimer, could enhance antigen-
specific responses up to 10,000 fold (3). However, the initial
potential of trimeric C3d, as a highly potent molecular adjuvant,
has not been realized and the reason(s) for this remain(s)
unclear. One possible explanation is that the artificial linear
trimer structure fails to represent naturally opsonised antigen,
and consequently does not provide sufficient CR cross-linking or
additional inflammatory signals for the B cell (or APC) activation
threshold to be reached. One possible approach to overcome this
is attaching more C3d to test antigens, but that approach is also
limited (42). In the light of these and other findings (11, 13, 43),
we considered that with understanding of the mode of action
of Sbi-III-IV we might be able to develop a new complement
activation based immune adjuvant.
The first clue to a mechanism for Sbi’s ability to rapidly
activate the AP came from monitoring Sbi-III-IV treated NHS
in a time course using anti-C3 and anti-Sbi immuno-blotting.
Here, we demonstrated that metastable C3b not only attaches
covalently to serum proteins but also to Sbi-III-IV itself; as a
transacylation target (Figure 1). This makes sense in the respect
that Sbi’s affinity to C3 obviously places it in close proximity to the
site of complement turnover and we speculate that C3b deposited
on Sbi-III-IV could help extend the fluid phase half-life of C3b,
preventing FH, and FI from binding and inactivating as normal,
perhaps similar to covalent adducts of C3b with IgG (44, 45).
However, as we have shown previously, Sbi-III-IV also
interacts with complement regulators FH and FHR-1, in addition
to binding C3b and its degradation products, thereby forming
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FIGURE 5 | Structural and functional analysis of the Sbi-III-IV-Ag85b fusion protein. (A) Schematic structure of the Sbi-III-IV-Ag85b fusion protein (see details of the
construct in Figure S5). (B) SAXS analysis of the fusion protein indicates a monomeric molecule with a radius of gyration of Rg = 3.7 nm and maximum particle size
of Dmax = 15 nm. The various molecular mass estimation range from 44 to 51 kDa and are comparable with a predicted monomer mass of 50 kDa. The 10
independent ab initio models obtained with DAMMIF are similar to each other, and according to the χ² values that estimate the goodness of the fit, the final structures
fit well with the experiment. More detailed modeling with Coral and EOM show that the flexibility of the missing structural information is restricted. (C) C3 activation
and C3-fragment deposition in NHS after incubation with Sbi-III-IV-Ag85b (100µM) or Ag85b (100µM), visualized using anti-Sbi and anti-C3d western blot analysis.
Resultant higher molecular weight bands with Sbi III-IV-Ag85b were identified as Sbi-III-IV-Ag85b with two covalently attached C3b α’ chains; Sbi-III-IV-Ag85b with
two iC3b α’-68 chains and Sbi-III-IV-Ag85b with two C3d molecules. Ag85b alone is unable to activate C3 as indicated by the presence of an intact C3 α-chain.
tripartite complexes (26). We next investigated whether Sbi-III-
IV acts as a competitive antagonist of FH via the recruitment
of FHR-1 and −5 into tripartite complexes and that FHR-1
can effectively displace FH from the tripartite complex. To this
end, data from our systematic site-directed mutagenesis screen
brought to light several Sbi mutants with complement activation
defects (Figure 1 and Figure S1). For instance, we demonstrated
that an alanine substitution in Sbi domain III at position 173
resulted in a dramatic reduction in C3 consumption activity
(Figure 1G). Notably, although a similar effect was observed with
a previously identified mutation in domain IV with impaired
C3d binding (R231A), K173A showed only slightly impaired C3d
binding capacity (Table 1) suggesting a different mechanism. We
therefore postulated that the K173A mutant would be ideal to
elucidate the structural and functional role of Sbi domain III
in the activation of complement and found that K173 in Sbi
domain III was crucial for the recruitment of FHR-5 and that the
K173A mutation only slightly affects FHR-1 binding (Figures 2,
3). These findings implicate a direct role of Sbi domain III in
the tripartite complex formation with these FHRs and that this
likely occurs via interactions with the C-terminal SCR domains
that share sequence identity with FH19−20. We confirm this by
showing that increasing concentrations of recombinant FHR-1,
FHR-2, FHR-5, and FH19−20 in serum indeed potentiate Sbi-
III-IV mediated C3 consumption, whilst the N-terminal SCRs
(FHR-11−2) fail to do this (Figure 3).
We also observed that Sbi greatly enhances the binding
of FHRs to C3b, thereby antagonizing FH activity, as shown
by the C3 convertase decay accelerating activity (DAA) assay
(Figures 3G,H). These results imply that the FHR-1 or FHR-
5 containing tripartite complexes can protect the AP C3
convertase, aiding the consumption of C3. These findings further
enhance the notion that the FHR family has diversified AP
de-regulatory functions, where FHR-1 seems more efficient in
counteracting the DAA of FH, whilst in contrast FHR-5 potently
antagonizes the cofactor activity (CA) of FH. The observed
Sbi-III-IV mediated shift in the complement regulatory balance
toward C3 activation could potentially be further enhanced by
the formation of homo/heterodimeric forms of FHR-1 with itself
and with other FHRs (FHR-2 and FHR-5) (12). These data
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FIGURE 6 | Sbi-III-IV is an effective adjuvant in mice. (A) Freshly prepared CD21−/− mouse serum was mixed with Sbi-III-IV-Ag85b or just Sbi-III-IV. The reaction was
stopped at various time points (0, 30, 60, 120min). Western blot was developed with rabbit anti-C3 at 1/1000 and goat anti-rabbit at 1/2000. C3d is shown as
confirmation that C3 has been activated and broken down. (N) is Cr2−/− serum incubated for 120min with saline. (B) C57Bl/6 mice (groups of 6) where immunized
intraperitoneally with either 2.7 µg Sbi-III-IV-Ag85b protein, 2 µg Ag85b, or 0.7 µg Sbi-III-IV plus 2 µg Ag85b in 150mM NaCl solution, followed by weekly bleed and
boosted (day 28) before terminal bleed at day 49. Serum IgG reactivity to Ag85b was measured over time by ELISA. Sera was diluted 1/50 and the mean absorbance
± SEM of each mouse group is shown. All data has been normalized to the day 0 average of all WT mice. (C) The previous experiment was repeated in C57Bl/6 mice
deficient of C3 (C3−/−)and complement receptor type I and 2 (Cr2−/−). Data is representative of at least 2 repeats (***P < 0.001, Student’s T-test, GraphPad Prism).
(D) Schematic representation of the dimeric Sbi-III-IV:C3d:FHR-1 solution structure providing a nidus for AP C3 convertase generation that overwhelms local
complement regulators, leading to the opsonisation of the nearby antigen surface by C3 break-down products that help facilitate the co-ligation of the B cell antigen
receptor (BCR) with complement receptor 2 (CR2) thereby lowering the threshold for B cell activation.
link to an ongoing evolutionary “arms race” where FH was
initially hijacked by S. aureus to protect it from complement
(46) and then FHRs (devoid of intrinsic complement regulatory
activity) were evolved/deployed by the host to compete with
FH on that surface and restore complement opsonisation of
the pathogen (22). Perhaps the release/secretion of Sbi from
S. aureus is a more recent event in this arms race with the
host, which takes the C3b/C3 convertase binding potential away
from the bacterial surface and leads to local rapid fluid phase
consumption of complement, i.e., local decomplementation and
bacterial survival/propagation. Our understanding of the role
and complexity of FHRs in immune evasion strategies is still in
its infancy (46), but this study underlines the potency of another
strategy in this process.
Using FHR-1 as a “model” dimerization domain containing
FHR, structural analysis of the Sbi-III-IV:C3d:FHR-1 tripartite
complex, using SAXS, indeed suggests the formation of a dimer
mediated by FHR-1 domain 1 and 2 and provides details of the
role of the extended unfolded nature of domain III in the binding
of FHR-1 (Figure 4). The molecular basis of the preferential
binding of FHR-1 over FH cannot easily be explained on the
basis of differences in amino acid sequence between the two
complement regulators, since their C3d binding regions (SCR 4–
5 of FHR-1 and SCR 19–20 of FH) share 99% sequence identity.
However, our SAXS analyses, and binding studies using C3d(g)
or iC3b as ligands (Figures 3, 4), indicate that the C-terminal
regions of FHR proteins are readily exposed, unlike those of FH
that exist in a “latent” conformation with the C-terminal part
of the protein folded back and partially blocked (47–50). The
dimeric physiological state of FHR-1 and the other FHRs tested
in this study is also likely to enhance their ability, due to increased
avidity, to assemble a tripartite complex.
Analysis of the hydrodynamic volume of the Sbi-III-IV:C3d
complex using switchSENSE highlighted a significant contraction
of the normally extended conformation Sbi-III-IV structure (34)
caused by the K173A substitution in domain III (Table 2). SAXS
analysis confirms these findings, showing a partially kinked
N-terminal structure of domain III in K173A with reduced
conformational freedom (Figures 4E–G). The contraction of the
Sbi-III-IV structure caused by the K173A substitution suggests
that the normally flexible and extended conformation of domain
III plays an important role in the recruitment of FHRs, especially
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FHR-5 into the tripartite complex after the initial interaction
between Sbi-IV and C3b. Previous structural analyses of the Sbi’s
domain III, using NMR, revealed that this domain is indeed
natively unfolded (51).
Based on the structural and functional information described
here we decided to construct a Sbi-III-IV-Ag85b fusion
construct that could be used to test its effect on the
immune response against this model antigen in vivo. We
chose Mycobacterium tuberculosis Ag85b, a fibronectin-binding
protein with mycolyltransferase activity (52), because it is
known to be immunogenic and previously suggested as a
vaccine candidate (53). Indeed, there is evidence that Ag85b
can elicit both humoral and cellular immune reactions in
patients with TB, but there is conflicting evidence of its efficacy
as a vaccine (54, 55), suggesting adjuvants may improve its
overall immunogenicity. This target also gives scope to allow
further testing in animal models of disease (56). Structural
analysis, using Circular Dichroism and SAXS confirmed that
secondary structural elements of both parent proteins have
been preserved in the fusion protein construct and that the
crucial functional Sbi domains are accessible for interactions
with complement (Figure 5 and Figure S5). We also show
that the Sbi-III-IV-Ag85b fusion construct can induce AP
activation and is opsonized with C3 breakdown products
(Figure 5C).
With AP activation in human and mouse serum confirmed
(Figures 5, 6), we opted to use straightforward immune response,
IgG titer, analysis to demonstrate the potential of Sbi-III-IV
to trigger complement in vivo and act as a vaccine adjuvant
in a mouse model, in a similar manner to many previous
studies (57). Our data herein firstly indicates that Sbi-III-IV can
activate mouse complement in an analogous manner to that
of the human complement system. This obviously allows direct
analysis of these pro-vaccine compounds in both mouse and
human model systems (a huge advantage to previous C3d based
adjuvants) (13), indeed Sbi-III-IV has acted as a C3 activator
in all species tested thus far (data not shown). As predicted
from the in vitro work, the opsonisation of fusion proteins
or co-immunized antigen by mouse complement breakdown
fragments results in a significant increase in the immunogenicity
of Ag85b, with increased IgG titres noted in the presence of
fused or co-immunized Ag85b (Figure 6). The adjuvant function
both increased the intensity of the response and the rate of
the response when compared to Ag85b immunized alone. We
will need to further explore the potency of this response to
that of common adjuvants and with a mix of target antigens
to fully assess the utility of Sbi-III-IV as a universal vaccine
adjuvant. For instance, comparison of the action of Sbi-III-IV to
the Glaxo-Smith-Kline’s adjuvant systems, particularly AS01 (58),
or to MF59 (59) may be of key interest and recent approaches
may provide ideal pre-clinical model systems to facilitate this
(60, 61) before progression to clinical studies. This is because
our data provides evidence of a 4-fold increase in humoral
response whilst AS01 has been demonstrated to have a much
more significant effect of T cell effector function (58). The work
is ongoing but the data herein demonstrate the initial proof of
concept.
In summary, we have demonstrated that Sbi-III-IV triggers
consumption of complement component C3 via activation of
the alternative complement pathway, by acting as a competitive
antagonist of FH via the recruitment of FHRs into dimeric
tripartite complexes that can protect C3b bound to Sbi
(Figure 6D). It is likely this provides a stable nidus for
alternative pathway mediated C3 convertase generation, i.e.,
local fluid phase C3bBb generation that overwhelms any local
complement regulators, providing the potential for bystander
lysis, or opsonisation of surfaces. Our ability to harness this
potential, targeting complement opsonisation to the surface of an
antigen (in this case fromMycobacterium) and therefore use Sbi-
III-IV as a vaccine adjuvant clearly demonstrates Sbi-III-IV has
great potential for use with a range of antigens across multiple
species, including humans, although more work remains to make
that a reality.
MATERIALS AND METHODS
Proteins, Antibodies, and Sera
Factor H (FH), C3b, factor B (FB), factor D (FD), factor
I (FI), properdin (FP), FI-depleted serum, goat anti-human
C3 polyserum, and goat anti-human FB polyserum were
purchased from Complement Technologies (Tyler, TX). FHR-
11−2, FHR-1, −2, and −5 used in the tripartite complex
reconstruction and binding competition assay were produced
using Chinese Hamster ovary cell culture [as previously
described Nichols et al. (62)]. Horse radish peroxidase (HRP)-
conjugated rabbit anti-goat immunoglobulin polyserum and
HRP-conjugated Streptavidin were acquired from Sigma Aldrich.
HRP-conjugated goat anti-rabbit immunoglobulin G (Thermo
Fisher, catalog no. 815-968-0747), HRP-conjugated rabbit anti-
mouse immunoglobulin G (Thermo Fisher, catalog no. 31452)
and biotin-conjugated FH monoclonal antibody OX24 (catalog
no. MA5-17735) were purchased from Thermo Fisher Scientific.
The goat anti-human FH polyclonal serum (catalog no. 341276-
1ml) that was previously used to detect human FH and
FHR-1 was purchased from Merck Millipore. Human C3
was purified from mixed pool citrated human plasma (TCS
Bioscience, PR100) using polyethylene glycol 4,000 precipitation,
anion, and cation exchange chromatography as previously
described (63). A pET15b-C3d construct was acquired from
Prof. David E. Isenman and transformed into Escherichia
coli (E. coli) stain BL21 (DE3), recombinant C3d was then
expressed, and purified using a previously described protocol
(64). Lyophilized normal human serum (NHS) was purchased
from Euro Diagnostica (catalog no. PC300). Additional proteins
and antibodies are described in the specific experimental
section.
Sbi-III-IV Constructs
The expression and purification of the N-terminally 6×His
tagged recombinant Sbi-III-IV from a pQE30:sbi-III-IV
construct were described previously (24).
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Sbi-III-IV Mutagenesis
Mutations in the Sbi-III-IV sequence were introduced using
the QuikChange II XL site-directed mutagenesis kit (Agilent
Technologies), the primers used are listed in Table S1. The
mutated pQE30:sbi-III-IV plasmids were sequenced to confirm
the success of the mutagenesis. SDS-PAGE profiles of all the Sbi-
III-IV mutant proteins used in this study are shown in Figure S1.
Sbi-III-IV Induced C3 Consumption Assay
Lyophilized NHS was re-suspended in chilled dH2O to a 2×
concentration. Equal volumes of 2×NHS and Sbi (10µM) were
combined. Sbi treated sera were then incubated in a thermocycler
at 37◦C for 30min. Treated serum samples were collected at
time intervals, 0.5 µl of serum was loaded on an SDS-PAGE gel
analyzed under reducing condition. The proteins were Western
blotted, and the blots were probed with anti-C3d, anti-Sbi, anti-
C3a or anti-factor B antibodies.
A hemolytic assay was modified from a previously published
procedure (65) to measure Sbi induced consumption of C3.
Briefly, rabbit erythrocytes (TCS Bioscience) were resuspended
in GVB buffer (5mM veronal, 145mM NaCl, 10µM EDTA, 0.1
% (w/v) gelatin) by washing three times via centrifugation at 600
g for 6min. The concentration of rabbit red cells to be used in
each experiment was determined by adding a stock of 5 µl of
erythrocytes to 245 µl of water to give complete lysis and then
re-adjusting cell concentration until an optical density reading
of 0.7 (A405) was reached. Lysis experiments were conducted
in two steps, first, 15 µl of NHS, 5 µl of Mg+-EGTA (70mM
MgCl2, and 100mM EGTA), 20 µl of protein in E2 buffer was
mixed and pre-incubated at 37◦C for 30min. Subsequently, 5 µl
of rabbit erythrocyte was added and incubated for an additional
30min at 37◦C. At the end of the incubation, 150µl of quenching
buffer (GVB supplemented with 10mM EDTA) was added. The
cells were pelleted by centrifugation at 1,500g for 10min, and
absorbance (A405) of 100 µl of supernatant measured. Post-
consumption lysis percentage was calculated as 100×((A405 test
sample-A405 0% control)/(A405 100%-A405 0% control)).
In vitro Complement Activation Assay in
Mouse Serum
Mouse serum was collected from male Cr2−/− mice by cardiac
puncture and allowed to clot fully on ice for 4 h followed by
separation of serum by centrifugation at 2,000 g in a refrigerated
centrifuge. Serum was then mixed with Sbi-III-IV or Sbi-III-
IV-Ag85b, ensuring that the amount of Sbi-III-IV in each
preparation was equivalent. The reaction was stopped at 0,
30, 60, and 120min, by the addition of reducing sample
buffer, boiled for 5min and analyzed on a 10% SDS-PAGE
gel. After transfer to nitrocellulose the blots were probed with
Rabbit anti-C3d (1/1000, DAKO, A0063) and Goat anti-Rabbit-
HRPO (1/2000, 111-035-046-JIR, Stratech), developed with ECL
substrate (Pierce), and exposed to X-Ray film for 2min.
Binding Kinetics and Hydrodynamic
Diameter Analysis
A switchSENSE DRX 2,400 instrument (Dynamic Biosensors)
was used to characterize the binding kinetics and protein size
changes based on switchSENSE technology (66, 67). Purified
Sbi-III-IV-cys, K173A, R231A, and their ligand C3d were sent
to Dynamic Biosensor’s protein analyzing facility for binding
kinetic and hydrodynamic diameter analysis. In the case of a
protein binding event, based on the real-time measurements
of the switching dynamics in a range of ligand concentrations,
binding rate constants (kON and kOFF) and dissociation constants
(KD) can be analyzed (67). Alternatively, under saturated binding
conditions, the switching dynamic of the protein (or protein
complex) can be compared with the switching dynamics of bare
DNA and with a biophysical model with which the size of the
immobilized protein (or protein complex) can be determined.
For determination of Sbi-III-IV:C3d binding kinetic parameters,
130, 100, 70, and 40 nM of C3d were applied sequentially onto
the Sbi-III-IV immobilized microchip. All Sbi:C3d complexes’
hydrodynamic diameters were estimated at a C3d concentration
of 130 nM.
Fluorometric C3b Breakdown Assay
Fluorometric C3b breakdown assay was performed using a
black 96 well microplate (Thermofisher, M33089) in a TECAN
Spark 20M temperature-controlled fluorescence plate reader.
Excitation was at 386 nm and emission was recorded at 475 nm
with a 20 nm bandwidth. The control C3b breakdown rate,
performed in PBS, contained 100 µl of 1µM C3b, 160 nM FH,
17 nM of FI and 10µM ANS, and was scanned every 5 s for
15min. To study the interruption of C3b breakdown, 32 nM of
FHR was either added alone or in combination with 1µM of
Sbi-III-IV. Data were collected at 25◦C, normalized by Excel
using the equation “Percentage of C3b=((FX-(F15min))/(F15min-
F0min))∗100” and plotted by Graphpad Prism.
Small Angle X-ray Scattering Analysis
Synchrotron radiation X-ray scattering from solutions of the Sbi-
III-IV:C3d:FHR-1 tripartite complex, the Sbi-III-IV(K173A):C3d
complex, and the Sbi-III-IV-Ag85b fusion protein were collected
at the EMBL P12 beamline of the storage ring PETRA III
(DESY, Hamburg, Germany). Images were collected using a
photon counting Pilatus-2M detector and a sample to detector
distance of 3.1m and a wavelength (λ) of 0.12 nm covering
the range of momentum transfer (s) 0.1 < s< 4.5 nm−1;
with s=4pisinθ/λ. Different solute concentrations were measured
using a continuous flow cell capillary. To monitor radiation
damage, 20 successive 50ms exposures were compared and
frames displaying significant alterations were discarded. The
data were normalized to intensity of the transmitted beam and
radially averaged; the scattering of the buffer was subtracted, and
the different curves were scaled for solute concentration. The
forward scattering I(0), the radius of gyration (Rg) along with
the probability distribution of the particle [p(r)] and the maximal
dimension (Dmax) were computed using the automated SAXS
data analysis pipeline SASFLOW (68).
For the Sbi-III-IV-Ag85b fusion protein data quality was
improved with SEC-SAXS mode and the parallel analysis of light
scattering data in a similar manner as described in Gräwert et al.
(69). Frames comprising solely the monomeric version of the
fusion protein were averaged and used for further processing
after background subtraction.
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The molecular masses (MM) were evaluated by comparison
of the forward scattering with that from a reference solution of
BSA and based on the Porod volumes of the constructs. With
SAXS, the former estimation of MM is within an error of 10%,
provided the sample and standard concentrate are determined
accurately. DAMMIF was used to compute the ab initio shape
models. For this, 10 independent models fitting the experimental
scattering curves were generated and compared to each other.
More detailed modeling was obtained with Coral. Here, existing
partial crystal structure of the Sbi-IV:C3d complex was extended
with 60 additional beads placed at the N-terminus of Sbi-IV to
mimic the missing Sbi-III domain. Here too, 10 independent
runs were performed, and the degree of variation addressed.
Further analysis of the flexibility of the samples was addressed
with Ensemble OptimizationMethod (EOM). For this, ensembles
of models with variable conformations are selected from a pool
of randomly generated models such that the scattering from the
ensemble fits the experimental data, and the distributions of the
overall parameters (e.g., Dmax) in the selected pool are compared
to the original pool.
The proteins in the Sbi-III-IV:C3d:FHR-1 tripartite complex
were combined 1:1:1 at a concentration of 45µM. The Sbi-III-
IV(K173A):C3d complex were formed at a 1:1 ratio at 240µM
(12 mg/ml). PDB structure 2wy8 (Sbi-IV:C3d complex) was used
to model the complex using and compared with SAXS data
previously recorded (34). The Sbi-III-IV-Ag85b fusion protein
was provided at 29, 72, and 145µM concentrations (1.45, 3.6,
and 7.2 mg/ml, respectively). The samples were dialysed against
PBS, which was also used for background subtraction. From
all samples concentration series were measured to exclude any
concentration dependent alterations.
Surface Plasmon Resonance Analysis
Tripartite complexes were analyzed by surface plasmon
resonance (SPR) technology using a Biacore S200 (GE
Healthcare). All experiments were conducted at 25◦C on
CM5 chips, using HBST (10mM HEPES, 150mM NaCl,
and 0.005% Tween 20, pH 7.4) as running buffer, which was
optionally supplemented with 1mM of MgCl2 (HBST+) to
be compatible with AP amplification condition. On the chip
surface 800 RU of C3b was opsonized via AP C3 convertase
through a method described before (70, 71). The iC3b surface
was produced by injecting of repetitive cycles of FH and
FI across a C3b opsonized surface, the completeness of the
conversion was confirmed by the inability of FB binding. A
separate chip surface was made by amine coupling 600 RU of
recombinant C3d (CompTech, USA). In all SPR experiments,
response differences were derived using the signal from a flow
cell to subtract the parallel reading from a reference flow cell
that blocked with carbodiimide, N-hydroxysuccinimide and
ethanolamine. Analytes were injected in duplicate (at 30 µl/min
for 200 s) followed by running buffer for 300 s and a regeneration
phase involving injection of regeneration buffer (10mM sodium
acetate, 1M NaCl pH 4.0) for 60 s. To analyze Sbi-III-IV binding
and the assembly of tripartite complex, concentration series
of Sbi-III-IV WT or K173A were flowed cross separately or
co-injected with FH, FHR-1, FHR-2, FHR-5, or FH19−20 at a
fixed concentration (100, 12.5, 20, 25, or 20 nM, respectively).
The C3 convertase DAA assay was performed on a CM5 chip
amine coupled with 500 RU C3b, using HBST+ as running buffer
throughout. A mixture of analytes for building C3 convertase
were flowed across, including FB and FD in addition to various
FH reagent combinations (FH or FH and FHR-1 or FH, FHR-
1 and −5). The various FH reagents combinations were also
flow across separately in order to derive the sensorgram for C3
convertase. To examining Sbi bound C3 convertase, 2µM of
wild-type Sbi-III-IV was added to the mixture of analytes for
building C3 convertase. The various FH reagent combinations
spiked with Sbi were flowed across separately in order to derive
the sensorgram for Sbi bound C3 convertase. Each injection cycle
includes Injection of the C3 convertase mixture for 200–300 s,
followed by running buffer for 300–400 s and two consecutive
60s regeneration phases.
FH/FHR-1 Competition Assay
C3b was diluted in carbonate buffer (pH 9.5) and coated on
to wells of a Nunc MaxiSorp plate (0.25 µg/well) for 16 h at
4◦C. The wells were blocked with PBST (PBS with 0.1% Tween
20) supplemented with and 2% BSA for 1 h at 37◦C, and then
washed with PBST buffer. Doubly diluted concentration series
(9-600 nM) of FHRs, FH19−20, FHR-11−2 in PBST-2% BSA were
then added to the wells, together with a constant concentration of
FH (25 nM) and Sbi-III-IV (1,000 nM). The plate was incubated
for 1 h at 37◦C, then washed with PBST. Fifty microliter of
monoclonal anti-FH antibody OX-24 (specific to the FH SCR
domain 5) diluted with PBS-2% BSA (0.6µg/ml) was added
to the wells and the plate incubated for a further 1 h. The
wells were washed with PBST, and 50 µl sheep anti-mouse IgG
(1:5000 dilution in PBST-2% BSA) was added to the wells for
1 h at 37◦C. The wells were washed again and the conjugate
was detected using TMB ELISA substrate solution, which was
added to the wells for 5min. The color reaction was stopped
by 10% H2SO4 and the plate was read at A450 using a plate
reader.
Design and Purification of the
Sbi-III-IV-Ag85b Fusion Construct
The DNA sequence coding for Sbi-III-IV (sbi448−798) was fused
to the 5’ end of the DNA sequence for Ag85b (ag85b121−975)
via a linker region of 84 bp (Figure S5A). The fusion gene
was commercially synthesized and ligated into the pET15b
vector, containing an ampicillin resistance cassette and a T7
promoter. The pET15b:sbi-III-IV-ag85b plasmid was verified
using sequencing, and the resulting construct encoded an N-
terminally his-tagged Sbi-III-IV-Ag85b protein. E. coli BL21
(DE3) cells harboring the pET15b:sbi-III-IV-ag85b plasmid were
grown in LB broth supplemented with 100µg/ml ampicillin
to an A600 = 0.4–0.6. Protein expression was induced with
0.5mM IPTG and by incubating the cells at 17◦C for 16 h.
Bacteria were harvested, lysed using sonication (80% amplitude,
for six 10 s bursts) in the presence of protease inhibitor
cocktail (set VII-Calbiochem, Merck), and the protein initially
purified using nickel-affinity chromatography (His-Trap column,
GE Healthcare) with a gradient of 0–0.5M imidazole in
50mM Tris, 150mM NaCl, pH 7.4. It was further purified
using size-exclusion chromatography (Hi-Load 16/60 Superdex
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S200 column, GE Healthcare) equilibrated in 20mM Tris,
150mM NaCl, pH 7.4. Fractions containing protein were
pooled and concentrated. Protein concentration was measured
at A280.
Analysis of Sbi-III-IV-Ag85b Fusion Protein
AP Complement Activity
Alternative pathway (AP) activity of Sbi III-IV-Ag85b-treated
NHS samples was analyzed using the ELISA-based WIESLAB R©
(Euro Diagnostica) complement system AP assay. Sbi-III-IV-
Ag85b was mixed with normal human serum (NHS) at a 1:1
volume ratio and incubated for 30min at 37◦C in a thermal
cycler. Treated serum was then diluted with AP diluent (blocking
the activation of the other two complement pathways) by 1 in 20.
From this point the manufacturer’s instructions were followed.
A blank (AP diluent), positive control (NHS) and negative
control (heat-inactivated NHS) were also recorded. Complement
activation was converted to residual AP activity (%) using the
equation: (sample - negative control)/(positive control - negative
control)× 100.
Analysis of C3 Fragment Deposition on
Sbi-III-IV-Ag85b Fusion Protein
The method used is similar to that described for WT Sbi-
III-IV. Lyophilised NHS (Euro Diagnostica) was re-suspended
in chilled dH2O. Sbi-III-IV-Ag85b (100µM) was mixed with
NHS in a 1:1 ratio, and incubated for 1 h at 37◦C in a
thermocycler. Samples were taken at regular intervals (0, 5,
15, 30, and 60min), and separated by SDS-PAGE followed
by Western blot analysis using either rabbit anti-Sbi (1.5:5000
dilution), rabbit anti-C3d (1.5:5000 dilution) or mouse anti-
Ag85b (1:1000 dilution) polyclonal antibodies and detected using
HRP-conjugated secondary antibodies (1:2500 goat anti rabbit
or 1:1000 goat anti mouse). NHS-only was used as a negative
control.
Measurement of Immune Response to
Sbi-III-IV-Ag85b Fusion Protein
Eight week old male C57bl/6 mice (wild-type, C3−/− and
Cr2−/−) were bled by tail vein venesection at day−2. Mice were
then immunized at day 0 with molar equivalent doses of Ag85b
alone (2 µg, a sub-optimal dose without adjuvant or boost, data
not shown), Sbi-III-IV-Ag85b (fusion protein), Sbi-III-IV alone
or a mixture of Sbi-III-IV and Ag85b, as appropriate. Mice were
then bled weekly thereafter and plasma stored at −80◦C until
required for batch analysis. Mice were boosted at day 28 and
sacrificed at day 42.
For analysis of IgG response to Ag85b by ELISA, 96 well plates
(NUNC maxisorb) were coated with 1µg/ml Ag85b (Abcam,
UK) or 1.35µg/ml Sbi-III-IV-Ag85b in carbonate buffer at 50 µl
per well and incubated at 4◦C for 16 h. Plates were washed with
0.01% PBS-Tween and a 1% BSA blocking solution was applied
for 1 h at 20◦C. Serum samples were diluted to 1/50 or 1/100 in
0.01% PBS-Tween, added at 50 µl per well and incubated for 1 h
at 20◦C. Plates were washed and secondary antibody (sheep anti
mouse IgG-HRPO, 515-035-071-JIR, Stratech, UK) was added
at 1/100 dilution, 50 µl per well and incubated for 1 h at 20◦C.
TMB substrate (50µl per well) was added and allowed to develop
for 6min. The reaction was stopped by the addition of 100 µl
10% H2SO4 per well and plates were read at A450. A mouse
monoclonal anti-Ag85b (Abcam, ab43019) used as a positive
control. The mean absorbance ± SEM of each mouse group is
shown. Data for each mouse, at time 0, has been normalized to
the day 0 average reactivity to Ag85b in all mice screened.
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